The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
May 2nd 2024
The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
Adding Dalpiciclib to Fulvestrant Prolongs Survival in HR–positive, HER2-negative Breast Cancer
February 17th 2022Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Read More
Expert: Cancer Screening Rates in 2021 Remain Lower Than Expected
February 2nd 2022Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.
Watch
Pharmacist Medication Insights: Abemaciclib (Verzenio) for Breast Cancer
January 28th 2022Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.
Watch
PI3K Inhibitors May Help Prevent Tamoxifen-Associated Uterine Cancer in Patients With Breast Cancer
December 14th 2021Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.
Read More
Breast Cancer Patients With Estrogen Receptor Mutations Benefit From Switch to Fulvestrant
December 7th 2021Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.
Read More
Daily Medication Pearl: Pertuzumab (Perjeta) Injection for Breast Cancer
November 19th 2021Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read More